{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
aTyr Pharma, Inc.
aTyr Pharma Hits 52-Week Low at $0.97 Amidst Significant Decline
aTyr Pharma, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, faces financial challenges, including a high price-to-book ratio and negative return on equity, while maintaining a volatile market presence.
aTyr Pharma Hits 52-Week Low at $1.00 Amidst Market Struggles
aTyr Pharma, Inc. has reached a new 52-week low of USD 1.00, reflecting a 47.41% decline over the past year. The company, with a market capitalization of USD 535 million, faces financial challenges, including a high price-to-book ratio and negative return on equity, amid ongoing industry volatility.
Is aTyr Pharma, Inc. overvalued or undervalued?
As of March 14, 2024, aTyr Pharma, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics, including a P/E ratio of NA, a Price to Book Value of 6.38, an EV to EBITDA of -6.14, and a troubling ROE of -84.50%, indicating it underperforms compared to peers like Chimerix and DiaMedica.
Is aTyr Pharma, Inc. technically bullish or bearish?
As of May 27, 2025, aTyr Pharma, Inc. shows a bullish trend supported by strong indicators like the MACD, moving averages, and Bollinger Bands, despite a mildly bearish signal from Dow Theory on the weekly chart.
Who are in the management team of aTyr Pharma, Inc.?
As of March 2022, the management team of aTyr Pharma, Inc. includes John Clarke (Independent Chairman), Sanjay Shukla (President and CEO), and several independent directors: Timothy Coughlin, Jane Gross, Jeffrey Hatfield, Svetlana Lucas, and Paul Schimmel. They oversee the company's strategic direction and operations.
What does aTyr Pharma, Inc. do?
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company focused on developing medicines for severe, rare diseases. It has a market cap of $457.48 million and reported a quarterly net loss of $15 million as of March 2025.
How big is aTyr Pharma, Inc.?
As of Jun 18, aTyr Pharma, Inc. has a market capitalization of 457.48 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -63.42 million over the latest four quarters. The company reported shareholder's funds of 70.02 million and total assets of 98.05 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
